Psychometric properties of the osteoporosis-specific morisky medication adherence scale in postmenopausal women with osteoporosis newly treated with bisphosphonates;Propiedades sicométricas de la escala morisky de adherencia a medicamentos específica para osteoporosis (OS-MMAS) en mujeres posmenopáusicas con osteoporosis nunca antes tratado con bisfosfonatos

Annals of Pharmacotherapy

Volumn 46, Issue 5, 2012, Pages 659-670

  Reynolds, Kristi ^a   Viswanathan, Hema N ^b   O'Malley, Cynthia D ^b   Muntner, Paul ^c   Harrison, Teresa N ^a   Craig Cheetham, T ^d   Hsu, Jin Wen Y ^a   Gold, Deborah T ^e   Silverman, Stuart ^f   Grauer, Andreas ^b   Morisky, Donald E ^g  

^a Kaiser Permanente Southern California ^*  (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Pharmacy Analytic Services   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adherence; Bisphosphonates; Morisky scale; Postmenopausal osteoporosis; Reliability; Validity

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; BELIEFS ABOUT MEDICINES QUESTIONNAIRE; CONSTRUCT VALIDITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM RATING SCALE; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; OSTEOPOROSIS SPECIFIC MORISKY MEDICATION ADHERENCE SCALE; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOMETRY; QUESTIONNAIRE; RATING SCALE; SCORING SYSTEM; SELF EFFICACY FOR APPROPRIATE MEDICATION USE SCALE; SELF REPORT; SHORT FORM 12; TEST RETEST RELIABILITY; TREATMENT SATISFACTION QUESTIONNAIRE FOR MEDICATION;

AGED; CALIFORNIA; DIPHOSPHONATES; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SURVEYS; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT SATISFACTION; POSTMENOPAUSE; PSYCHOMETRICS; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SELF EFFICACY; SELF REPORT;

EID: 84861011830     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q652     Document Type: Article

References (40)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-795.
2. National Osteoporosis Foundation. Fast facts. www.nof.org/node/40 (accessed 15 Jul 2011).
3. Dempster DW, Lindsay R. Pathogenesis of osteoporosis. Lancet 1993; 341:797-801.
4. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22:465-475. DOI 10.1359/jbmr.061113
5. Boonen S, Laan RF, Barton IP, Watts NB. Effect of osteoporosis treat ments on risk of non-vertebral fractures: review and meta-analysis of in tention-to-treat studies. Osteoporos Int 2005;16:1291-1298. DOI 10.1007/s00198-005-1945-x
6. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-578.
7. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280: 2077-2082.
8. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-1022.
9. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with osteoporosis drug therapy and risk of fracture. Osteoporos Int 2007;18:271-277. DOI 10.1007/s00198-006-0230-y
10. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 2007;82:1493-1501.
11. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006;38:922-928. DOI 10.1016/j.bone.2005.10.022
12. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209-216.
13. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005;80:856-861.
14. Lekkerkerker F, Kanis JA, Alsayed N, et al. Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 2007;18:1311-1317. DOI 10.1007/s00198-007-0410-4
15. Warriner AH, Curtis JR. Adherence to osteoporosis treatments: room for improvement. Curr Opin Rheumatol 2009;21:356-362. DOI 10.1097/BOR.0b013e32832c6aa4
16. Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE, Muntner P. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care 2009;15:59-66.
17. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 2008;10:348-354.
18. Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004;2:12. DOI 10.1186/1477-7525-2-12. Those seeking information regarding or permission to use the TSQM are directed to Quintiles, Inc. at www.quintiles.com/TSQM or TSQM@quintiles. com.
19. Dimenas E, Glise H, Hallerback B, Hernqvist H, Svedlund J, Wiklund I. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol 1993; 28:681-687.
20. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychology and Health 1999;14:1-24.
21. Revicki DA, Wood M, Wiklund I, Crawley J. Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroe-sophageal reflux disease. Qual Life Res 1998;7:75-83.
22. Risser J, Jacobson TA, Kripalani S. Development and psychometric evaluation of the Self-efficacy for Appropriate Medication Use Scale (SEAMS) in low-literacy patients with chronic disease. J Nurs Meas 2007;15:203-219.
23. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-233.
24. Gorsuch R. Factor analysis. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates, 1983.
25. Tinsley HEA, Tnisley DJ. Uses of factor analysis in counseling psychology research. J Counseling Psychology 1987;34:414-424.
26. Cronbach LJ. Coefficient alpha and internal structure tests. Psychometrika 1951;16:297-334.
27. Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999;2:113-127. DOI 10.1046/j.1524- 4733.1999.02210.x
28. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989;45:255-268.
29. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-174.
30. Bentler PM. Comparative fit indexes in structural models. Psychol Bull 1990;107:238- 46.
31. Browne M, Cudeck R. Alternative ways of assessing model fit. Socio Methods Res 1992;21:230-259.
32. Hatcher L. A step-by-step approach to using the SAS system for factor analysis and structural equation modeling. Cary, NC: SAS Publishing, 1994.
33. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487-497. DOI 10.1056/NEJMra050100
34. Palacios S, Sanchez-Borrego R, Neyro JL, Quereda F, Vazquez F, Perez M. Knowledge and compliance from patients with postmenopausal osteoporosis treatment. Menopause Int 2009;15:113-119. DOI 10.1258/mi.2009.009029
35. Turbi C, Herrero-Beaumont G, Acebes JC, et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of post-menopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 2004;26:245-256.
36. Breuil V, Cortet B, Cotte FE, et al. Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women. Osteoporos Int 2012;23:445-455. DOI 10.1007/s00198-011-1555-8
37. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24:67-74.
38. DeVellis R. Reliability (24- 42). In: Scale development-theory and applications applied social research methods series. Volume 26. Newbury Park, CA: Sage Publications Inc., 1991.
39. Clifford S, Barber N, Horne R. Understanding different beliefs held by adherers, unintentional nonadherers, and intentional nonadherers: application of the Necessity-Concerns Framework. J Psychosom Res 2008; 64:41-46. DOI 10.1016/j.jpsychores.2007.05.004
40. McHorney CA, Gadkari AS. Individual patients hold different beliefs to prescription medications to which they persist vs nonpersist and persist vs nonfulfill. Patient Prefer Adherence 2010;4:187-195.